LGND - Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B
IEX Last Trade
105.63
-0.230 -0.218%
Share volume: 113,893
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$105.86
-0.23
-0.22%
Fundamental analysis
40%
Profitability
22%
Dept financing
24%
Liquidity
75%
Performance
54%
Performance
5 Days
1.91%
1 Month
-3.91%
3 Months
26.01%
6 Months
25.43%
1 Year
59.84%
2 Year
13.70%
Key data
Stock price
$105.63
DAY RANGE
N/A - $107.00
52 WEEK RANGE
$49.24 - $112.13
52 WEEK CHANGE
$0.59
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: John Higgins
Region: US
Website: https://www.ligand.com/
Employees: 130
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.ligand.com/
Employees: 130
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.
Recent news